Supplementary Materials

Supplementary Material for:

Alkylphosphocholine Analogs for Broad-Spectrum Cancer Imaging and Therapy

Jamey P. Weichert,* Paul A. Clark, Irawati K. Kandela, Abram M. Vaccaro, William Clarke, Marc A. Longino, Anatoly N. Pinchuk, Mohammed Farhoud, Kyle I. Swanson, John M. Floberg, Joseph Grudzinski, Benjamin Titz, Anne M. Traynor, Hong-En Chen, Lance T. Hall, Christopher J. Pazoles, Perry J. Pickhardt, John S. Kuo*

*Corresponding author. E-mail: (J.P.W.); (J.S.K.)

Published 11 June 2014, Sci. Transl. Med. 6, 240ra75 (2014)
DOI: 10.1126/scitranslmed.3007646

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Preferential cancer cell uptake of CLR1501.
  • Fig. S2. Preferential 125I-CLR1404 uptake and retention in cancer cells in vitro.
  • Fig. S3. Uptake and retention of 125I-CLR1404 after lipid raft disruption in prostate carcinoma cells.
  • Fig. S4: Flow cytometry analysis of CLR1501 GSC labeling.
  • Fig. S5. In vivo time course of biodistribution and tumor uptake of 124I-CLR1404 and 18F-FDG in a prostate tumor model.
  • Fig. S6. Dual modality PET/CT virtual colonoscopy in rodents.
  • Fig. S7. Tumor growth and animal survival after 131I-CLR1404 therapy.
  • Fig. S8. Recurrent World Health Organization grade III astrocytoma.
  • Fig. S9. 131I-CLR1404 SPECT/CT imaging of metastatic colorectal cancer.
  • Fig. S10. Synthesis of optical APC analogs.
  • Table S1. 124I-CLR1404 uptake in tumor xenografts.
  • Table S2. Patient information.
  • References (3740)
  • Legends for Movies S1 and S2

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Movie S1. (.avi format). Cellular uptake of CLR1501 in prostate cancer cells.
  • Movie S2. (.avi format). Dual modality PET/CT virtual colonoscopy in the Pirc rat model.